PDGFC facilitates enzalutamide resistance in prostate cancer through activation of the Rap1-MAPK pathway
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Platelet-Derived Growth Factor C (PDGFC) drives enzalutamide resistance in prostate cancer (PCa) by activating signaling pathways. Targeting PDGFC or its associated pathways offers a new therapeutic strategy for resistant PCa.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Prostate cancer (PCa) is a heterogeneous malignancy with metastatic potential.
- Enzalutamide (EnzaR) is effective but resistance inevitably develops.
- Mechanisms underlying enzalutamide resistance in PCa are not fully understood.
Purpose Of The Study
- To investigate the role of Platelet-Derived Growth Factor C (PDGFC) in enzalutamide resistance in prostate cancer.
- To elucidate the molecular mechanisms by which PDGFC contributes to resistance.
- To evaluate PDGFC as a potential therapeutic target for resistant prostate cancer.
Main Methods
- Quantitative real-time PCR and Western blot to measure PDGFC expression.
- In vitro and in vivo assays (CCK8, colony formation, EdU, xenograft models) to assess PCa cell phenotypes.
- Luciferase and chromatin immunoprecipitation assays to determine STAT4-mediated regulation of PDGFC.
Main Results
- PDGFC expression is significantly elevated in enzalutamide-resistant PCa (EnzaR PCa) and correlates with proliferation.
- Silencing PDGFC enhances EnzaR PCa cell sensitivity to enzalutamide, inhibiting progression.
- Overexpression of PDGFC activates the PDGFR-Rap1-MAPK pathway in an autocrine manner.
- PDGFR inhibitors, alone or with enzalutamide, inhibit xenograft progression.
- STAT4 transcription factor binds to the PDGFC promoter, upregulating PDGFC.
Conclusions
- PDGFC plays a pivotal role in the development of enzalutamide resistance in prostate cancer.
- Targeting PDGFC or the PDGFC-mediated Rap1-MAPK pathway represents a promising therapeutic strategy for EnzaR PCa.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...